



CORRECTIONS MEDICINE
Extended Naltrexone Administration Policy
ACA Standard: 4 ALDF – 4C – 37

Effective: May 2019
Revised: August 2019
Reviewed:

Policy Number:
CM – 28.2

- I. **PURPOSE:** To provide incarcerated individuals in the Buzz Westfall Justice Center who have substance use disorders with extended release naltrexone products.
- II. **POLICY:** It is the policy of Saint Louis County Department of Public Health (DPH) Corrections Medicine program to provide patients with extended release naltrexone products (XR-NTX) for FDA approved indication of substance use disorders (SUD). All patients who receive XR-NTX shall first see a provider who shall make a diagnosis of an appropriate SUD and engage in shared decision making with the patient about his/her treatment options.
- III. **RESPONSIBILITY:** All Corrections Medicine staff are responsible for the content of this policy and procedure, as well as adherence to the policy.
- IV. **PROCEDURE:** The following procedure outlines requirements to receive XR-NTX for any patient who has seen a medical provider who recommends and has prescribed XR-NTX.
 1. Clinical assessment
 - a. Patients who are currently receiving naltrexone products will be referred to the Medication Assisted Treatment (MAT) program for evaluation.
 - b. The patient shall be scheduled for a clinic appointment with a medical provider who will engage with the patient to determine if XR-NTX is an appropriate therapeutic option.
 1. The nurse shall verify that the patient has had the appropriate required lab testing and if it has not been done, the laboratory testing will be ordered using the appropriate standing order.
 - c. The provider shall review the laboratory test results and determine if the patient should receive the XR-NTX injection.
 - d. If the patient is approved to receive an XR-NTX injection, the provider will write an order for the medication.
 - e. The patient shall then be scheduled for a clinic visit for administration of the XR-NTX injection. The XR-NTX injection shall be given no more than seven (7) days before being released from the Buzz Westfall Justice Center.
 2. Naloxone Challenge

- a. Candidates for administration of XR-NTX shall have an adequate period of abstinence, of at least 7 days, and should have no signs of opioid or alcohol withdrawal. Nursing staff shall assess for abstinence by:
 - i. Asking patient for history of last use,
 - ii. Obtaining a set of vitals, and
 - iii. Completing a point of care urine drug screen, if positive the provider should be notified and the urine sent to the laboratory for confirmatory testing.
 - b. If history and drug screen are negative, and the patient has been incarcerated for more than seven (7) days, proceed with XR-NTX administration.
 - c. All patients who have been in custody for less than 7 days with a negative history and drug screen who are to receive XR-NTX shall undergo a naloxone challenge test prior to administration, which consists of a small dose of oral naloxone to verify that the patient will not have precipitated withdrawal and it is safe to administer the long acting XR-NTX injection.
3. XR-NTX Administration
- a. The Nurse shall perform an assessment to include, but not limited to:
 - i. History of any substance use and last date of substance use
 - ii. History of any alcohol or opioids in last seven (7) days
 - iii. Pharmacy name and location (if taking medications while incarcerated)
 - iv. Vital Signs
 - a. Nurse shall obtain a urine specimen and perform a point of care urine drug screen and urine beta human chorionic gonadotropin (bHCG) (if patient is female) and document test results in the EMR at every visit. Inject CR-NT intramuscularly via deep intramuscular (IM) route into gluteal region and push suspension in slowly.
 - b. The patient will be observed after administration of the injection for any symptoms of withdrawal or any adverse reactions prior to being transferred to their housing unit.

V. **REFERENCE:**

American Correctional Association: Performance –Based Standards for Adult Local Detention Facilities, fourth edition; Standard 4ALDF-4C-37